Ena/VASP-EVH1 inhibition prevents chemotaxis and metastasis by blocking the EVH1–WAVE2 interaction
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2423512122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Matthias Müller und 13 weiteren Autor:innen. Beteiligte Einrichtung: PROSION Therapeutics, Köln 50931, Germany. Hauptthemen laut MEDLINE: Chemotaxis, Microfilament Proteins, Wiskott-Aldrich Syndrome Protein Family, DNA-Binding Proteins. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bundesministerium für Bildung und Forschung (BMBF), EC | Horizon Europe | | HORIZON EUROPE European Innovation Council (EIC), ZonMw (Netherlands Organisation for Health Research and Development).
Abstract (Originalsprache)
Cancer therapy would benefit from suppressing cancer cell motility in the process of metastasis. Such directed cell migration relies on the propulsive force established by the filamentous actin network within lamellipodia. Proteins of the Ena/VASP family and the WAVE regulatory complex orchestrate lamellar protrusions and therefore provide promising targets for pharmacological interventions. Here, we report a cross-talk between Ena/VASP proteins and WAVE2 that is important for cancer cell extravasation. Mutating the EVH1 domain recognition motif in WAVE2 abrogates chemotaxis of triple-negative MDA-MB-231 breast cancer cells and reduces their extravasation in a zebrafish model. In pilot experiments, orthotopic implantation of these cells into mice led to a reduction in macrometastasis, resulting in prolonged survival. Similarly, intervention by an Ena/VASP-EVH1 inhibitor also reduced metastasis in vivo. Our results suggest that pharmacological interference with the Ena/VASP–WAVE2 interaction may thus reduce metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PROSION Therapeutics, Köln 50931, Germany.
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin 13125, Germany.
- Translational Immunology, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin 10117, Germany.
- Oncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden 2333, The Netherlands.
- Department of Chemistry, University of Cologne, Köln 50939, Germany.
ORCID-Profile: Matthias Müller, Matthias Barone, Maarten van Dinther, Jenny Eichhorst, Martin Lehmann, Hartmut Oschkinat, Hans-Günther Schmalz, Peter Ten Dijke, Ronald Kühne
Förderung
- Bundesministerium für Bildung und Forschung (BMBF)
- EC | Horizon Europe | | HORIZON EUROPE European Innovation Council (EIC)
- ZonMw (Netherlands Organisation for Health Research and Development)
- Health~Holland (LSH)
- EC | Horizon Europe | 創新的歐洲 | HORIZON EUROPE European Innovation Council
Zitieren
APA
Müller, M., Barone, M., Dinther, M. V., Motzny, K., Ren, J., Eichhorst, J., Albat, D., Chiha, S., Lehmann, M., Volkmer, R., Oschkinat, H., Schmalz, H. G., Ten Dijke, P., & Kühne, R. (2025). Ena/VASP-EVH1 inhibition prevents chemotaxis and metastasis by blocking the EVH1–WAVE2 interaction. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2423512122
Vancouver
Müller M, Barone M, Dinther MV, Motzny K, Ren J, Eichhorst J, et al. Ena/VASP-EVH1 inhibition prevents chemotaxis and metastasis by blocking the EVH1–WAVE2 interaction. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2423512122
BibTeX
@article{Mller2025,
author = {Müller, Matthias and Barone, Matthias and Dinther, Maarten van and Motzny, Kathrin and Ren, Jiang and Eichhorst, Jenny and Albat, Dominik and Chiha, Slim and Lehmann, Martin and Volkmer, Rudolf and Oschkinat, Hartmut and Schmalz, Hans-Günther and Ten Dijke, Peter and Kühne, Ronald},
title = {Ena/VASP-EVH1 inhibition prevents chemotaxis and metastasis by blocking the EVH1–WAVE2 interaction},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2423512122}
}
EUVIMED